Circassia is developing a novel inhaled combination therapy based on innovative technology that combines multiple pharmaceutical ingredients. This ‘triple’ fixed-dose combination targets the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD).
The company’s ‘triple’ COPD treatment candidate combines three therapies in a novel formulation delivered via a simple-to-use pressurized metered dose inhaler. The product contains a long-acting beta agonist and long-acting muscarinic antagonist combined in single particles and an inhaled corticosteroid. The novel formulation has recently completed a first-in-human clinical study and the results show there were no significant safety or tolerability concerns. In addition, each of the product components were bioavailable following inhalation. As a result, the study provides an important clinical foundation, and because the product does not fit Circassia’s strategy focusing on specialist or substitutable medicines the company plans to partner it for further development and commercialization.
Pipeline status: Triple combination
Registration Study /